+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Alzheimer's Disease Theranostics

  • ID: 4612928
  • Book
  • January 2019
  • Region: Global
  • 80 Pages
  • Elsevier Science and Technology
1 of 3

Alzheimer's Disease Theranostics discusses the latest information on recent theranostic avenues for both the diagnosis and treatment of Alzheimer's patients. It presents the pros and cons of the probable mechanistic role of nanoparticles in crossing the blood-brain barrier and improving disease symptoms. Finally, it highlights the merits of existing maneuvers and suggests perspectives to aid in future developments. Despite the difficulty of drug delivery to the brain, there are some nanoparticulate platforms demonstrating promise in treating neurodegenerative disorders such as Alzheimer's disease. Manifold theranostic maneuvers include antioxidants, natural bioactive compounds, gene therapy, and nanotechnological approaches, all of which are discussed in this important work.

  • Examines various theranostic applications for the diagnosis and treatment of Alzheimer's disease
  • Features a comprehensive overview of nanoparticle therapeutics in the area and use of antioxidants
  • Assesses the common challenges and lessons learned from blood-brain barrier challenges, viral vector approaches and mitochondria-targeted therapeutics

Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.

Note: Product cover images may vary from those shown
2 of 3

1. Introduction: Alzheimer's Disease Pathology and Therapeutics 2. Early Diagnosis of Alzheimer's Disease: Pros and Cons 3. Antioxidants in Alzheimer's Therapy 4. Natural Compounds in the Treatment of Alzheimer's Disease 5. Blood Brain Barrier 6. Gene Therapy: The Cornerstone in the Development of Alzheimer's Disease Therapeutics 7. Viral vector therapeutics against Alzheimer's Disease 8. Mitochondria-Targeted Nanoparticles: A Milestone or a Mirage in the Treatment of Alzheimer's Disease 9. Nanoparticles: The Double-Edged Swords 10. Alzheimer Therapeutics: Pros and Cons

Note: Product cover images may vary from those shown
3 of 3


4 of 3
Obulesu, Magisetty
M. Obulesu is a Scientist in ATG Laboratories, Pune, India. He has 19 years of research and teaching experience. His research areas are multifarious which include food science, pathology of Neurodegenerative diseases such as Alzheimer's disease and designing polymer based Biomaterials (Design of hydrogels etc.). He did Alzheimer's disease research and developed an aluminium induced neurotoxicity rabbit model. His present research focuses on development of redox-active injectable hydrogels of polyion complex. His research area also includes development of metal chelators to overcome metal induced toxicity. His books, 3 monographs entitled "Alzheimer's Disease Theranostics (Elsevier (First Edition))” "Parkinson's Disease Therapeutics: Emphasis on Nanotechnological Advances” (Elsevier (First Edition)), "Turmeric and Curcumin for Neurodegenerative Diseases (Elsevier (First Edition))” and an editorial collection "Phytomedicine and Alzheimer's Disease (Taylor and Francis (First Edition))” are accepted currently. He is the first and corresponding author for majority of his articles. He secured a certificate from Stanford University for the Scientific Writing course. He is on editorial board of a few pathology journals such as Journal of Medical Laboratory and Diagnosis, Journal of Medical and Surgical Pathology, Annals of Retrovirals and Antiretrovirals, Kenkyu Journal of Medical Science and Clinical Research, SciFed Oncology and Cancer Research Journal, Journal of Cancer and Cure. He is also on editorial board of nanotechnology journals such as SciFed Nanotech Research Letters, SciFed Drug Delivery Research, Current Updates in Nanotechnology and Journal of Nanotechnology and Materials Science.
Note: Product cover images may vary from those shown